Simplex Trading, LLC Tcr2 Therapeutics Inc. Transaction History

Simplex Trading, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 27, 2023	BUY	$1.0 - $1.62 $1,444 - $2,339	1,444 New	1,444 $2,000
Q2 2022 Aug 03, 2022	SELL	$2.11 - $2.94 $4,810 - $6,703	-2,280 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$2.4 - $4.71 $4,255 - $8,350	1,773 Added 349.7%	2,280 $6,000
Q4 2021 Feb 23, 2022	BUY	$4.58 - $8.34 $2,322 - $4,228	507 New	507 $2,000
Q1 2021 Apr 26, 2021	SELL	$20.38 - $34.07 $26,820 - $44,836	-1,316 Closed	0 $0
Q4 2020 Feb 02, 2021	SELL	$19.0 - $32.63 $9,614 - $16,510	-506 Reduced 27.77%	1,316 $40,000
Q3 2020 Oct 14, 2020	BUY	$13.1 - $20.69 $18,824 - $29,731	1,437 Added 373.25%	1,822 $37,000
Q2 2020 Jul 13, 2020	BUY	$6.51 - $16.85 $1,074 - $2,780	165 Added 75.0%	385 $5,000
Q1 2020 Apr 29, 2020	BUY	$6.01 - $16.01 $1,322 - $3,522	220 New	220 $1,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.